Health Library › Health News

Health News

A new biomarker may help spot cte during life, but it’s early

A preliminary study has found a potential clue in the long search for a way to diagnose chronic traumatic encephalopathy,

Article Updated: November 14, 2026 5 min read

A preliminary study has found a potential clue in the long search for a way to diagnose chronic traumatic encephalopathy, or CTE, while a person is still alive. Researchers reported that a tau biomarker called eMTBR-tau243 was higher in people with advanced CTE than in healthy controls. The work is early, but it adds to growing interest in blood and spinal fluid markers that could one day help doctors separate CTE from other brain diseases with overlapping symptoms.

The findings do not establish a clinical test. They suggest a possible direction for future research, especially because CTE still can be confirmed only after death by examining brain tissue. That limitation has made it difficult for families and clinicians to know whether memory problems, mood changes or other symptoms are being caused by CTE or by another neurodegenerative disorder.

What happened in the study

The new research, published in JAMA and reported by the Associated Press, examined eMTBR-tau243 in cerebrospinal fluid and blood across multiple groups. In the CTE subgroup, the biomarker was higher in people with advanced disease than in healthy controls, but it did not reliably identify early-stage CTE. The study also found that the marker was elevated in some other mixed tau disorders, including Alzheimer’s disease and certain forms of frontotemporal lobar degeneration.

That matters because CTE is not the only illness tied to tau buildup in the brain. The study’s authors and outside experts stressed that the result is promising but far from definitive. The sample of people with CTE was small, and the research does not show that the biomarker alone can diagnose the disease in routine care.

Advertisement

Why this matters for brain health

CTE has drawn increasing attention because it is associated with repeated head impacts and can be linked to symptoms such as memory loss, changes in mood, and thinking problems. But those symptoms are not unique to CTE. They can also appear in Alzheimer’s disease, frontotemporal dementia and other conditions. That overlap is one reason the lack of a living diagnosis has been such a barrier for patients, researchers and clinicians.

In the study, the biomarker signal was strongest in later-stage disease, which suggests it may be more useful as a marker of more advanced tau pathology than as a stand-alone screening tool. That is still important, though, because even a marker that works best later in the illness could help researchers define who has CTE during life and how the disease progresses over time.

What the evidence actually shows

The most careful reading of the study is that eMTBR-tau243 may reflect mixed tau pathology rather than being specific to CTE alone. The JAMA paper reports that plasma and cerebrospinal fluid levels were increased in people with Alzheimer’s disease, high-stage CTE, and a subset of genetic frontotemporal lobar degeneration cases, compared with cognitively unimpaired controls. In other words, the biomarker appears linked to certain tau-driven brain changes, but not to one disease exclusively.

The authors wrote that the finding raises the possibility of using the biomarker, along with a history of repetitive head impacts and other biomarker patterns, to identify people who may be more likely to have CTE pathology during life. That is an important distinction. It is not the same as saying a blood test can diagnose CTE on its own.

That caution is consistent with broader federal research guidance. The National Institute of Neurological Disorders and Stroke says it is supporting work to refine diagnostic criteria for CTE and to validate biomarkers that may one day help detect CTE in living people rather than only through autopsy. The institute also notes that biomarker development is still a research goal, not a finished clinical tool.

What remains uncertain

Several major questions remain. First, the study group was small, especially for the CTE samples. Small studies can reveal signals that disappear when tested in larger, more diverse populations. Second, the marker was not useful for early-stage CTE in this report, which limits how soon it might help in real-world diagnosis. Third, because similar tau abnormalities show up in other brain diseases, researchers still need to figure out how much diagnostic value the marker has after accounting for age, overlapping disorders and other clinical factors.

Advertisement

There is also the broader issue of what any biomarker should do. A useful test would need to do more than signal that something is wrong. It would need to help clinicians distinguish CTE from other conditions, perform well across different stages of disease, and hold up in studies that follow patients over time. The new work does not yet meet that standard.

Still, experts have long hoped for progress in this area because CTE research has been constrained by the fact that diagnosis has traditionally depended on brain examination after death. Moving from postmortem confirmation toward antemortem detection would be a major advance, but it will require larger validation studies and probably more than one biomarker.

What this could mean in practical terms

For now, people who are worried about memory loss, personality changes, worsening mood, or other cognitive symptoms should not interpret this study as proof that they have CTE. Those symptoms deserve medical attention, but they can come from many causes. A clinician may consider a full neurological evaluation, review of head injury history, cognitive testing, and other laboratory or imaging work if appropriate.

If symptoms are sudden, severe, or accompanied by weakness, trouble speaking, new confusion, or loss of consciousness, urgent medical care is warranted. Those features can signal a medical emergency and should not be watched and waited on at home.

For people with a history of repeated head impacts, the research may be encouraging because it shows that scientists are getting closer to objective measures of disease biology. But the most important takeaway is also the most cautious one: the biomarker is a promising clue, not a diagnostic answer. The path from a research finding to a routine test is usually long, and in CTE that path is still being built.

The bottom line

This study adds to a growing body of evidence that fluid biomarkers may one day help identify CTE during life. The signal in eMTBR-tau243 is intriguing, especially in advanced disease, but the work is preliminary and needs much larger confirmation. For now, it is a research milestone rather than a clinical breakthrough.

Sources

What dementia warning signs can look like in everyday life Next article → What dementia warning signs can look like in everyday life

Was this article helpful?

Free newsletter

Get the Daily Health View briefing

The day's most important health news, explained clearly. One short email a day. Unsubscribe anytime.

Share this article

Found this useful? Share it with someone who may benefit from it.

Author

Daily Health View Editorial Team

Health & Wellness Editorial Desk

The Daily Health View Editorial Team prepares educational health content with an emphasis on clarity, responsible presentation and reference-based information.

Daily Health View Editorial content Updated November 14, 2026